$4.71
10.11% yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
US2307701092
Symbol
CPIX
Sector
Industry

Cumberland Pharmaceuticals Inc. Stock price

$4.71
+0.18 3.97% 1M
+3.59 320.54% 6M
+2.34 98.73% YTD
+3.21 214.00% 1Y
+2.46 109.33% 3Y
+1.04 28.34% 5Y
-2.07 30.53% 10Y
Nasdaq, Closing price Fri, May 16 2025
-0.53 10.11%
ISIN
US2307701092
Symbol
CPIX
Sector
Industry

Key metrics

Market capitalization $78.40m
Enterprise Value $73.41m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 13.72
EV/Sales (TTM) EV/Sales 1.79
P/S ratio (TTM) P/S ratio 1.91
P/B ratio (TTM) P/B ratio 2.74
Revenue growth (TTM) Revenue growth 5.82%
Revenue (TTM) Revenue $41.08m
EBIT (operating result TTM) EBIT $-3.66m
Free Cash Flow (TTM) Free Cash Flow $5.35m
Cash position $15.11m
EPS (TTM) EPS $-0.24
Short interest 1.11%
Show more

Is Cumberland Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Cumberland Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:

Buy
100%

Financial data from Cumberland Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
41 41
6% 6%
100%
- Direct Costs 11 11
0% 0%
27%
30 30
8% 8%
73%
- Selling and Administrative Expenses 23 23
1% 1%
55%
- Research and Development Expense 4.95 4.95
10% 10%
12%
2.26 2.26
372% 372%
6%
- Depreciation and Amortization 5.92 5.92
1% 1%
14%
EBIT (Operating Income) EBIT -3.66 -3.66
46% 46%
-9%
Net Profit -3.28 -3.28
61% 61%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Cumberland Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cumberland Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
3 days ago
Cumberland leveraging Qureight's deep-learning AI platform  for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England , May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced a partnership with Qureight, a Core Imaging Labo...
Neutral
Seeking Alpha
7 days ago
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX ) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Conference Call Participants Operator Good afternoon, and welcome to the Cumberland Pharmaceuticals First Quarter 2025 Financial Report and Comp...
Neutral
PRNewsWire
10 days ago
NASHVILLE, Tenn. , May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period.
More Cumberland Pharmaceuticals Inc. News

Company Profile

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Head office United States
CEO A. Kazimi
Employees 91
Founded 1999
Website www.cumberlandpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today